GMA306

-

 

GMA306, an M-Body composed of an antagonistic antibody against ETa and a TGF-β trap, is aimed to treat severe PAH and lung tissue fibrosis. It retains an equal efficacy in relieving vasoconstriction to the standalone anti-ETa antibody (GMA301), with the additional effect in ameliorating the pulmonary artery vascular remodeling and slowing the blood vessel and lung tissue fibrosis, GMA306 is the next generation drug for PAH and lung tissue fibrosis，and may become a special treatment for severe PAH patients with vascular and lung tissue fibrosis.